Up a level |
Childs, Alexa, Zakeri, Nekisa, Ma, Yuk Ting, O'Rourke, Joanne, Ross, Paul, Hashem, Essam, Hubner, Richard A, Hockenhull, Kimberley, Iwuji, Chinenye, Khan, Sam et al (show 9 more authors)
(2021)
Biopsy for advanced hepatocellular carcinoma: results of a multicentre UK audit.
BRITISH JOURNAL OF CANCER, 125 (10).
pp. 1350-1355.
Labeur, Tim A, Berhane, Sarah, Edeline, Julien, Blanc, Jean-Frederic, Bettinger, Dominik, Meyer, Tim, Van Vugt, Jeroen LA, Ten Cate, David WG, De Man, Robert A, Eskens, Ferry ALM et al (show 6 more authors)
(2020)
Improved survival prediction and comparison of prognostic models for patients with hepatocellular carcinoma treated with sorafenib.
LIVER INTERNATIONAL, 40 (1).
pp. 215-228.
Sarker, Debashis, Plummer, Ruth, Meyer, Tim, Sodergren, Mikael H, Basu, Bristi, Chee, Cheng Ean, Huang, Kai-Wen, Palmer, Daniel H ORCID: 0000-0002-7147-5703, Ting, Yuk, Evans, TR Jeff et al (show 26 more authors)
(2020)
MTL-CEBPA, a Small Activating RNA Therapeutic Upregulating C/EBP-a, in Patients with Advanced Liver Cancer: A First-in-Human, Multicenter, Open-Label, Phase I Trial.
CLINICAL CANCER RESEARCH, 26 (15).
pp. 3936-3946.
Jones, Robert P ORCID: 0000-0001-5608-001X, Psarelli, Eftychia-Eirini ORCID: 0000-0002-3102-0288, Jackson, Richard, Ghaneh, Paula, Halloran, Christopher M ORCID: 0000-0002-5471-4178, Palmer, Daniel H ORCID: 0000-0002-7147-5703, Campbell, Fiona, Valle, Juan W, Faluyi, Olusola, O'Reilly, Derek A et al (show 92 more authors)
(2019)
Patterns of Recurrence After Resection of Pancreatic Ductal Adenocarcinoma: A Secondary Analysis of the ESPAC-4 Randomized Adjuvant Chemotherapy Trial.
JAMA SURGERY, 154 (11).
pp. 1038-1048.
Han, Guohong, Berhane, Sarah, Toyoda, Hidenori, Bettinger, Dominik, Elshaarawy, Omar, Chan, Anthony WH, Kirstein, Martha, Mosconi, Cristina, Hucke, Florian, Palmer, Daniel ORCID: 0000-0002-7147-5703 et al (show 24 more authors)
(2020)
Prediction of Survival Among Patients Receiving Transarterial Chemoembolization for Hepatocellular Carcinoma: A Response-Based Approach.
Hepatology (Baltimore, Md.), 72 (01).
pp. 198-212.
Vogel, Arndt, Kelley, Robin Katie, Johnson, Philip ORCID: 0000-0003-1404-0209, Merle, Philippe, Yau, Thomas, Kudo, Masatoshi, Meyer, Tim and Rimassa, Lorenza
(2023)
Predictive and prognostic potential of liver function assessment in patients with advanced hepatocellular carcinoma: a systematic literature review.
LIVER CANCER, 12 (4).
pp. 372-391.
Meyer, Tim, Fox, Richard, Ma, Yuk Ting, Ross, Paul J, James, Martin W, Sturgess, Richard, Stubbs, Clive, Stocken, Deborah D, Wall, Lucy, Watkinson, Anthony et al (show 8 more authors)
(2017)
Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial.
LANCET GASTROENTEROLOGY & HEPATOLOGY, 2 (8).
pp. 565-575.
Waked, Imam, Berhane, Sarah, Toyoda, Hidenori, Chan, Stephen L, Stern, Nicholas, Palmer, Daniel ORCID: 0000-0002-7147-5703, Tada, Toshifumi, Yeo, Winnie, Mo, Frankie, Bettinger, Dominik et al (show 9 more authors)
(2017)
Transarterial chemo-embolisation of hepatocellular carcinoma: impact of liver function and vascular invasion.
BRITISH JOURNAL OF CANCER, 116 (4).
pp. 448-454.
Meyer, Tim and Johnson, Philip ORCID: 0000-0003-1404-0209
(2019)
Trial endpoints for systemic therapy in patients with hepatocellular carcinoma.
JOURNAL OF HEPATOLOGY, 70 (6).
pp. 1060-1061.
Hashimoto, Ayumi, Sarker, Debashis, Reebye, Vikash, Jarvis, Sheba, Sodergren, Mikael H, Kossenkov, Andrew, Sanseviero, Emilio, Raulf, Nina, Vasara, Jenni, Andrikakou, Pinelopi et al (show 21 more authors)
(2021)
Upregulation of C/EBPα Inhibits Suppressive Activity of Myeloid Cells and Potentiates Antitumor Response in Mice and Patients with Cancer.
CLINICAL CANCER RESEARCH, 27 (21).
pp. 5961-5978.
Meyer, Tim, Palmer, Daniel H ORCID: 0000-0002-7147-5703, Cheng, Ann-Lii, Hocke, Julia, Loembe, Arsene-Bienvenu and Yen, Chia-Jui
(2017)
mRECIST to predict survival in advanced hepatocellular carcinoma: Analysis of two randomised phase II trials comparing nintedanib vs sorafenib.
LIVER INTERNATIONAL, 37 (07).
pp. 1047-1055.